Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
5
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
immunotherapy
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
gene therapy
gilead sciences
novartis
cancer immunotherapy
clinical trials
glaxosmithkline
johnson & johnson
merck
alzheimer's disease
amgen
biogen
What
bio
roundup
drug
abbvie’s
acquisitions
ahead
albert
american
annual
approval
ash
biggest
biofourmis
biogen’s
biopharma
biopharmaceutical
blood
borne
bourla
bucks
cancer
cancers
car
celebrate
celgene
ceo
chance
colleagues
companies
company
conference
convo
corner
crispr
day
days
diego
earlier
exome
failures
Language
unknown
unset
Current search:
immunotherapy
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
